Hospitalized COVID patients test Anti-Nausea shot
NCT ID NCT04470622
Summary
This study tested whether adding an injectable form of aprepitant—a medication normally used to prevent nausea—to standard hospital care could help adults recently hospitalized with COVID-19. Researchers wanted to see if it helped patients get discharged sooner and prevented them from needing breathing machines. The trial was small and ended early, so it did not provide clear answers about the treatment's effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Helen Keller Hospital
Sheffield, Alabama, 35660, United States
-
University of California, Irvine Medical Center
Orange, California, 92868, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.